Folfoirinox Added 4 mos to Gem- Pegph20 Added 6 mos * to Folfirinox- The Combo May Cure High Hyal Patients
Fol-Peg Represents an Exciting Fully Owned Halozyme Rx in Ph2 Clinical Trials With Hope of FDA Breakthrough Status and Expeditied Review
Phase 4b Panc Ca Surv- Gem alone- 7 mos, Fol- alone 11 mos, Gem-PegpH20- 17+ mos*
* in High Hyaluron Tumors
I am surprised given how deadly pancreatic cancer is, the estimated primary completion date is December 2017 (4 years from start date) and the Estimated Study Completion Date: May 2019. Maybe with good results they approve it earlier.
Estimated Enrollment: 172
Study Start Date: December 2013
Estimated Study Completion Date: May 2019
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
These primary completion dates are in years because they are measuring survival rates.
In contrast, for example, the fast insulin program studies are completed much more quickly because their primary endpoints are very different.
I doubt Pegph20 would be partnered for use with Gemcitabine or Abraxane or both at only 5% of revenue. It is a stand alone drug capable of Breaking open some solid tumors and suppressing mets (if the data bears out) and should command the same premium regardless of whether it is used with generics or chemo drugs under patent. I believe the folfirinox trial has only to do with latest SOC.